NAPLEX Quiz: Primary Literature Evaluation

What this quiz covers

This quiz focuses on Primary Literature Evaluation, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Add spironolactone 25 mg daily because the trial showed no hyperkalemia discontinuations with mineralocorticoid receptor antagonists in chronic kidney disease
2. Add finerenone 10 mg daily with potassium monitoring because the trial demonstrated a clinically meaningful reduction in kidney outcomes in a similar population on angiotensin-converting enzyme inhibitor therapy (correct answer)
3. Avoid finerenone because the hazard ratio confidence interval crosses 1.0, indicating no benefit over placebo
4. Switch lisinopril to losartan because the trial compared finerenone only to angiotensin receptor blockers and not to angiotensin-converting enzyme inhibitors

Explanation: This question tests the application of primary literature on finerenone to a patient with diabetic kidney disease. The patient matches the trial population with type 2 diabetes, albuminuria despite ACE inhibitor therapy, and eGFR in the 25-60 range requiring the 10 mg starting dose. The correct answer (B) appropriately applies the trial's significant kidney outcome benefit (HR 0.82, p=0.001) with necessary potassium monitoring given the 2.3% hyperkalemia discontinuation rate. Option A incorrectly suggests spironolactone and misinterprets the hyperkalemia data. Option C misunderstands statistical significance - the confidence interval (0.73-0.93) does not cross 1.0, confirming benefit. Option D incorrectly assumes the trial excluded ACE inhibitor users when it included both ACE inhibitors and ARBs. When applying renal outcome trials, match the patient to inclusion criteria, use appropriate dosing for renal function, and implement safety monitoring protocols from the trial.

Question 2

1. Recommend starting aspirin because the hazard ratio below 1.0 confirms cardiovascular benefit regardless of p-value
2. Recommend against starting aspirin for primary prevention because there was no cardiovascular benefit and there was a statistically significant increase in major bleeding (correct answer)
3. Recommend aspirin only if ibuprofen is continued because nonsteroidal anti-inflammatory drugs reduce bleeding risk when combined with aspirin
4. Recommend aspirin because the trial excluded patients with chronic kidney disease, so the bleeding results do not apply to him

Explanation: This question evaluates application of primary prevention aspirin trials in elderly patients with bleeding risk factors. The patient is over 70 with CKD and regular NSAID use, both increasing bleeding risk. The correct answer (B) appropriately interprets that aspirin showed no cardiovascular benefit (p=0.40) while significantly increasing major bleeding (HR 1.38, p<0.001), supporting recommendations against primary prevention. Option A incorrectly focuses on the hazard ratio direction without considering statistical significance. Option C dangerously suggests NSAIDs reduce aspirin bleeding risk when they actually increase it. Option D incorrectly claims CKD patients were excluded - the trial's broad elderly population would include various comorbidities. Primary prevention decisions require weighing absolute risk reduction against harm; when benefit is absent and harm is significant, especially with additional bleeding risk factors, aspirin should be avoided.

Question 3

1. Adding ezetimibe provides a modest but statistically significant reduction in cardiovascular events and is reasonable to add for secondary prevention (correct answer)
2. Ezetimibe should not be added because the hazard ratio is greater than 1.0
3. Ezetimibe is indicated only for primary prevention, so the study is not applicable
4. The results are invalid because the study was observational and subject to confounding

Explanation: This question assesses the clinical significance of modest hazard ratio reductions in cardiovascular outcomes trials. The key study is a randomized, double-blind trial of ezetimibe added to statins in ASCVD patients, showing a small but significant reduction in composite CV events. The correct answer supports adding ezetimibe for its evidence-based benefit in secondary prevention for this patient with elevated LDL on maximal statin. Choice B misinterprets HR 0.94>0 as no benefit despite CI excluding 1.0; choice C wrongly limits to primary prevention; choice D errs in calling it observational. Common errors include dismissing small absolute reductions as irrelevant. Pearl: Incremental LDL lowering with adjuncts like ezetimibe can provide additive CV risk reduction. Framework: Evaluate add-on therapies by absolute risk reduction and number needed to treat for patient discussions.

Question 4

1. Apixaban demonstrated lower stroke/systemic embolism and lower major bleeding than warfarin, supporting apixaban as an appropriate option for this patient (correct answer)
2. Warfarin is preferred because the confidence interval crosses 1.0 for stroke/systemic embolism
3. Apixaban should be avoided because the trial was not randomized and therefore cannot inform therapy
4. The results apply only to patients with creatinine clearance <30 mL/min, so they are not applicable here

Explanation: This question evaluates the interpretation of hazard ratios and confidence intervals in superiority trials for anticoagulation outcomes. The key study is a randomized, open-label trial with blinded endpoints comparing apixaban to warfarin in nonvalvular atrial fibrillation, showing lower stroke and bleeding risks with apixaban. The correct answer supports apixaban as appropriate because it demonstrated superior efficacy and safety in a population including those with CrCl >25 mL/min, applicable to this patient's CrCl of 55. Choice B is incorrect as the CI 0.66–0.95 does not cross 1.0, indicating significance; choice C errs in stating the trial was not randomized; choice D misstates the applicability, as the trial included a range of renal functions. Common misinterpretations include confusing open-label with non-randomized designs. A clinical pearl is to prioritize randomized controlled trials for causal inferences in treatment decisions. Framework: Verify if CI excludes the null value (1.0 for ratios) to confirm statistical significance before applying to patients.

Question 5

1. The trial was randomized and double-blind, so lack of external validity is not a concern for any patient with asthma
2. The active comparator was inhaled corticosteroid dose escalation, but adherence and inhaler technique were not objectively verified, which could bias exacerbation outcomes (correct answer)
3. Because p=0.01, the exacerbation reduction is clinically meaningless and should be ignored
4. The study is a cohort study, so confounding fully explains the observed benefit of tiotropium

Explanation: This question tests critical appraisal of study limitations in asthma trials. The patient has moderate persistent asthma with exacerbations despite combination therapy. The correct answer (B) identifies a key limitation: while the trial was randomized and double-blind, adherence and inhaler technique verification could significantly impact exacerbation outcomes when comparing add-on therapy versus ICS escalation. Option A incorrectly dismisses external validity concerns in well-designed trials. Option C misinterprets statistical significance - p=0.01 confirms the difference is real, not clinically meaningless. Option D incorrectly identifies the study design as cohort when it's clearly described as randomized. When evaluating asthma trials, consider that poor adherence and technique are common reasons for apparent treatment failure, and trials without objective verification may not reflect real-world effectiveness differences.

Question 6

1. Apixaban is preferred because it reduced major bleeding compared with rivaroxaban without loss of effectiveness for stroke prevention in the studied population (correct answer)
2. Rivaroxaban is preferred because an open-label design always overestimates bleeding with twice-daily regimens, making apixaban appear safer
3. Neither agent should be used because similar stroke outcomes prove both drugs are ineffective compared with no anticoagulation
4. Rivaroxaban is preferred because the confidence interval for bleeding includes 1.0, indicating no statistically significant difference

Explanation: This question evaluates interpretation of a pragmatic head-to-head comparison of direct oral anticoagulants in atrial fibrillation. The patient has nonvalvular atrial fibrillation with prior GI bleeding, making bleeding risk particularly relevant. The correct answer (A) accurately interprets that apixaban significantly reduced major bleeding (HR 0.74, p=0.006) compared to rivaroxaban while maintaining similar stroke prevention efficacy. Option B incorrectly dismisses the bleeding difference by misunderstanding open-label design limitations - these typically underestimate, not overestimate, differences. Option C misinterprets similar stroke outcomes as ineffectiveness rather than equivalence. Option D incorrectly states the bleeding confidence interval includes 1.0 when it actually excludes it (0.60-0.92). When evaluating comparative effectiveness trials, focus on clinically meaningful differences in safety when efficacy is similar, and recognize that pragmatic designs enhance real-world applicability despite open-label limitations.

Question 7

1. Aspirin because it had less major bleeding and similar venous thromboembolism recurrence
2. Rivaroxaban because it substantially reduced recurrent venous thromboembolism versus aspirin without a statistically significant increase in major bleeding (correct answer)
3. Neither option because the major bleeding p-value indicates rivaroxaban is definitively more dangerous
4. Aspirin because hazard ratio <1.0 indicates rivaroxaban is less effective

Explanation: This question assesses risk-benefit in extended anticoagulation trials. The key study factor is the randomized trial showing lower VTE recurrence with rivaroxaban versus aspirin, with non-significant bleeding increase. The correct answer prefers rivaroxaban for its substantial efficacy benefit without significant bleeding rise in this recurrent VTE patient. Choice A misprioritizes small bleeding difference; choice C overinterprets p=0.60; choice D errs on HR<1.0 meaning. A common error is equating non-significance to definitive safety. Pearl: For recurrent VTE, weigh recurrence risk against bleeding in agent selection. Framework: Calculate NNT and NNH from event rates for personalized anticoagulation decisions.

Question 8

1. Either lisinopril or amlodipine is reasonable for blood pressure lowering; selection should consider adverse-effect profiles and patient preference (correct answer)
2. Lisinopril is superior because it caused more cough, indicating stronger blood pressure effect
3. Amlodipine is contraindicated because edema occurred more often, so it should never be used for hypertension
4. Neither agent should be used because similar blood pressure reduction means both are ineffective

Explanation: This question evaluates interpreting adverse event profiles in equivalence trials for hypertension. The key study factor is the randomized trial showing similar BP reduction but differing side effects between lisinopril and amlodipine. The correct answer deems either reasonable, selected by preference and adverse profiles for this uncomplicated patient. Choice B mislinks cough to efficacy; choice C overstates edema as contraindication; choice D wrongly sees similarity as ineffectiveness. A common error is dismissing agents based on class side effects alone. Pearl: Tailor antihypertensives to patient lifestyle and tolerability. Framework: In similar-efficacy scenarios, prioritize patient-centered factors like dosing and side effects.

Question 9

1. Doxylamine/pyridoxine provides a small but statistically significant symptom improvement and is a reasonable option with counseling about somnolence (correct answer)
2. Doxylamine/pyridoxine should be avoided because any somnolence rate above placebo indicates unacceptable harm
3. Placebo is preferred because the improvement difference is less than 1 point, which proves no benefit
4. The findings cannot be applied because randomized trials are unethical in pregnancy and therefore invalid

Explanation: This question tests minimal clinically important differences in symptom-based trials. The key study factor is the randomized, double-blind trial showing small symptom improvement with doxylamine/pyridoxine versus placebo in pregnancy, with mild somnolence increase. The correct answer notes its modest benefit as reasonable with somnolence counseling for this patient. Choice B overstates somnolence as unacceptable; choice C dismisses small difference as no benefit; choice D wrongly questions RCT ethics in pregnancy. A common error is requiring large effects for significance. Pearl: In nausea of pregnancy, start with non-pharmacologic then evidence-based options. Framework: Define MCID thresholds to assess clinical relevance beyond p-values.

Question 10

1. Add finerenone because it reduced kidney outcomes compared with placebo in a similar population, with potassium monitoring for hyperkalemia (correct answer)
2. Avoid finerenone because the hazard ratio is less than 1.0, indicating worse kidney outcomes
3. Add finerenone only if estimated glomerular filtration rate is >90 mL/min/1.73 m$^2$ because that was the trial population
4. Do not add finerenone because p=0.001 indicates the benefit is due to chance

Explanation: This question evaluates applying cardiorenal outcome trials to similar populations. The key study is a randomized, double-blind trial of finerenone versus placebo in diabetic kidney disease, showing reduced kidney composite with hyperkalemia risk. The correct answer supports adding finerenone for its benefit in this albuminuric CKD patient on RAS blockade, with monitoring. Choice B misinterprets HR<1.0 as harm; choice C errs on eGFR inclusion; choice D wrongly sees p=0.001 as chance. Common misinterpretations involve reversing ratio directions. Pearl: Mineralocorticoid antagonists like finerenone offer renoprotection in CKD with monitoring. Framework: Confirm patient alignment with trial baseline characteristics like UACR and eGFR.

Question 11

1. Use a 5-day total course if he meets clinical stability criteria because cure rates were similar and adverse events were lower (correct answer)
2. Use a 10-day course because the confidence interval includes negative values, proving 5 days is inferior
3. Use a 14-day course because shorter durations were not studied in pneumonia
4. Avoid early discharge because the trial was randomized and therefore not applicable to real patients

Explanation: This question tests applying duration-of-therapy trials to de-escalation decisions. The key study is a randomized trial showing similar cure with fewer adverse events for 5 versus 10 days in stable pneumonia patients. The correct answer supports a 5-day course for this improving patient, reducing adverse events. Choice B misinterprets CI; choice C assumes longer is better without evidence; choice D errs on randomization limiting applicability. Common misinterpretations include fearing shorter durations without data. Pearl: Shorter antibiotic courses minimize resistance and harm when efficacy is equivalent. Framework: Evaluate duration trials by clinical stability criteria for safe de-escalation.

Question 12

1. Dapagliflozin reduced cardiovascular death/worsening heart failure and is clinically meaningful to add to guideline-directed therapy in an eligible patient like this (correct answer)
2. Dapagliflozin should only be used in patients with type 1 diabetes, so the results do not apply
3. The hazard ratio indicates harm because it is less than 1.0
4. The findings are not applicable because the trial included only patients with estimated glomerular filtration rate >90 mL/min/1.73 m$^2$

Explanation: This question tests the application of composite outcomes and hazard ratios in heart failure trials to patient care. The key study is a randomized, double-blind trial of dapagliflozin versus placebo in HFrEF patients, including those without diabetes and with eGFR as low as 30 mL/min/1.73 m². The correct answer highlights dapagliflozin's reduction in CV death/worsening HF as clinically meaningful for this eligible patient on guideline therapy. Choice B is incorrect as the trial included non-diabetics; choice C misinterprets HR<1.0 as harm; choice D errs as the trial allowed eGFR ≥30, matching this patient's 48. Common misinterpretations involve misunderstanding inclusion criteria. Pearl: SGLT2 inhibitors offer cardiorenal benefits beyond glycemic control in HFrEF. Framework: When applying trial results, confirm patient matches key eligibility criteria like eGFR and comorbidities.

Question 13

1. Add finasteride if he has prostate enlargement because it reduced progression outcomes (retention/surgery) versus placebo, with counseling on sexual adverse effects (correct answer)
2. Do not add finasteride because a relative risk of 0.50 means the risk doubled
3. Add finasteride only for immediate symptom relief within days because that is what the trial measured
4. Avoid finasteride because the p-value indicates the difference is not statistically significant

Explanation: This question evaluates relative risk reduction in long-term BPH trials. The key study factor is the randomized, double-blind trial showing reduced progression (retention/surgery) with finasteride add-on versus placebo in enlarged prostate, with sexual side effects. The correct answer supports adding finasteride for this symptomatic patient with counseling on side effects. Choice B misinterprets RR 0.50 as doubling risk; choice C errs on timeline for benefits; choice D wrongly sees p=0.006 as non-significant. A common error is confusing risk metrics. Pearl: 5-ARIs like finasteride prevent BPH progression over months to years. Framework: Assess long-term outcomes like surgery avoidance in chronic condition trials.

Question 14

1. There was no statistically significant difference between strategies; either dose escalation or switching is reasonable, guided by adherence and cost (correct answer)
2. Switching to esomeprazole is clearly superior because 74% is greater than 78%
3. Doubling omeprazole is contraindicated because the confidence interval includes negative values
4. The p-value of 0.26 proves the two treatments are identical in all patients

Explanation: This question tests non-inferiority interpretation when no significant difference is found. The key study factor is the randomized trial showing similar symptom control with omeprazole dose escalation versus esomeprazole switch. The correct answer concludes either strategy is reasonable, guided by practical factors like adherence and cost for this patient. Choice B miscalculates percentages; choice C errs on CI meaning; choice D overinterprets p=0.26 as proving identity. A common error is assuming no difference means superiority of one. Pearl: For GERD non-responders, optimize PPI before advanced interventions. Framework: In equivalence trials, use CIs to assess if differences fall within predefined margins.

Question 15

1. Because it was an observational cohort study, residual confounding may explain the similar fracture rates and limits causal conclusions (correct answer)
2. Because the p-value is >0.05, denosumab is proven superior to alendronate
3. Because it was open-label, fracture outcomes cannot be measured objectively
4. Because it was pragmatic, the results cannot be applied to real-world patients

Explanation: This question evaluates limitations of observational designs in comparative effectiveness research. The key study is a pragmatic, open-label cohort study comparing denosumab to alendronate, showing similar fracture rates but higher adherence with denosumab. The correct answer identifies residual confounding as a limitation due to the observational nature, relevant for this adherence-challenged patient. Choice B misinterprets p>0.05 as proving superiority; choice C wrongly claims open-label prevents objective outcomes; choice D confuses pragmatic with inapplicable. Common errors include treating cohorts as equivalent to RCTs. Pearl: Observational studies are useful for real-world data but require caution for causality. Framework: Assess study design hierarchy; prioritize RCTs for efficacy, cohorts for effectiveness and adherence insights.

Question 16

1. Escalate to triple therapy because it reduced exacerbations compared with dual bronchodilation, while weighing increased pneumonia risk (correct answer)
2. Continue current therapy because the confidence interval includes 1.0 for exacerbations
3. Switch to inhaled corticosteroid monotherapy because it reduces pneumonia risk compared with triple therapy
4. Avoid triple therapy because a lower rate ratio indicates more exacerbations

Explanation: This question tests weighing efficacy against safety in escalation trials for COPD. The key study is a randomized, double-blind trial showing fewer exacerbations with triple therapy but more pneumonia versus dual bronchodilation. The correct answer supports escalating to triple therapy for this frequent exacerbator, balancing benefits with pneumonia risk. Choice B misinterprets CI excluding 1.0; choice C wrongly suggests ICS monotherapy; choice D errs on rate ratio<1 indicating harm. Common misinterpretations include focusing solely on one outcome. Pearl: In COPD, use exacerbation history to guide inhaled therapy escalation. Framework: Balance composite efficacy endpoints with specific adverse event rates in respiratory trials.

Question 17

1. Duloxetine may offer modest pain reduction versus placebo; consider patient goals and tolerability, and monitor for adverse effects (correct answer)
2. Duloxetine should be started because p=0.004 guarantees a large improvement in function for all patients
3. Avoid duloxetine because the difference in pain score is negative, indicating worse pain
4. Do not use duloxetine because placebo-controlled trials cannot be used for pain management decisions

Explanation: This question evaluates balancing modest pain relief with adverse effects in chronic pain trials. The key study is a randomized, double-blind trial showing small pain score improvement with duloxetine versus placebo, but higher nausea and discontinuations. The correct answer suggests duloxetine as an option with monitoring and goal discussions for this patient. Choice B overstates p=0.004 significance; choice C misreads negative difference as worse; choice D dismisses placebo-controlled trials. Common misinterpretations include expecting dramatic improvements in chronic conditions. Pearl: Multimodal approaches often needed for chronic pain management. Framework: Use effect sizes and tolerability data to inform shared decisions in pain literature.

Question 18

1. Adalimumab is highly effective for plaque psoriasis, but screening for infection risk (including tuberculosis) is essential because excluded populations limit applicability (correct answer)
2. Adalimumab should be avoided because placebo had a higher response rate
3. The large p-value indicates adalimumab is ineffective
4. The results apply only to patients with active tuberculosis because they were included in the trial

Explanation: This question assesses the impact of exclusion criteria on safety considerations in biologic trials. The key study factor is the randomized, double-blind trial of adalimumab versus placebo in psoriasis, excluding active infections and untreated latent TB. The correct answer highlights adalimumab's efficacy but stresses infection screening due to exclusions limiting applicability. Choice B misreads response rates; choice C errs on p-value meaning; choice D wrongly states TB inclusion. A common misinterpretation is ignoring exclusions in risk assessment. Pearl: For immunosuppressants, always screen for infections per guidelines before initiation. Framework: Evaluate trial exclusions to identify gaps in safety data for high-risk patients.

Question 19

1. Consider aripiprazole augmentation as an evidence-based option while counseling on and monitoring for akathisia (correct answer)
2. Avoid aripiprazole because the number needed to treat indicates no benefit when it is greater than 1
3. Prefer placebo augmentation because it had fewer adverse effects and equal remission rates
4. Do not apply the findings because randomized trials cannot be used to guide depression treatment

Explanation: This question tests balancing efficacy benefits with adverse event risks in augmentation trials for depression. The key study factor is the randomized, double-blind trial showing higher remission with aripiprazole augmentation but increased akathisia. The correct answer considers aripiprazole as evidence-based while monitoring for akathisia, applicable to this partial responder. Choice B misinterprets NNT>1 as no benefit; choice C wrongly prefers placebo due to equal remission misread; choice D dismisses RCTs for depression. A common misinterpretation is overlooking tolerability in favor of efficacy alone. Pearl: Augmentation strategies should weigh NNT against NNH in shared decision-making. Framework: Use metrics like NNT and NNH to quantify benefits and harms when applying psychiatric trial data.

Question 20

1. Exclusion of decompensated cirrhosis limits applicability to patients with advanced liver disease, so liver function status must be considered before applying results (correct answer)
2. Use of placebo makes the trial nonrandomized and therefore invalid
3. A high sustained virologic response rate means the regimen is safe for all liver disease severities
4. Because p<0.001, the regimen is effective only for patients with decompensated cirrhosis

Explanation: This question assesses the impact of exclusion criteria on generalizability in infectious disease trials. The key study factor is the randomized trial of a pan-genotypic HCV regimen excluding decompensated cirrhosis, showing high SVR versus placebo. The correct answer identifies exclusion of advanced liver disease as limiting applicability, relevant if this patient's status is severe. Choice B misstates placebo use affecting randomization; choice C overgeneralizes safety; choice D errs on p-value implication. Common misinterpretations include ignoring exclusions for safety. Pearl: Assess liver function staging before HCV treatment selection. Framework: Review trial exclusions to ensure patient safety when extrapolating efficacy data.